Thalidomide in multiple myeloma

Bibliography

• JEMAL A, MURRAY T, WARD E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
   PubMed Web of Science ®Google Scholar
• GAHRTON G, DURIE BG, SAMSON D: Multiple myeloma and related disorders. Arnold Publishers, London (2005).
   Google Scholar
• ALEXANIAN R, HAUT A, KHAN AU et al.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 208(9):1680-1685.
   PubMed Web of Science ®Google Scholar
• MYELOMA TRIALISTS’ COLLABORATIVE GROUP: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. (1998) 16(12):3832-3842.
   PubMed Web of Science ®Google Scholar
• MCELWAIN TJ, POWLES RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet (1983) 2(8354):822-824.
   PubMed Web of Science ®Google Scholar
• CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. (2003) 348(19):1875-1883.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. (1996) 335(2):91-97.
   PubMed Web of Science ®Google Scholar
• BLADE J, ROSINOL L, SUREDA A et al.: High-dose therapy intensification versus continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood (2005) 106(12):3755-3759.
   PubMed Web of Science ®Google Scholar
• FERMAND JP, RAVAUD P, CHEVRET S et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood (1998) 92(9):3131-3136.
   PubMed Web of Science ®Google Scholar
• SAN MIGUEL JF, GARCIA-SANZ R: Myeloma: update on supportive care strategies. Curr. Treat. Options. Oncol (2003) 4(3):247-258.
   PubMedGoogle Scholar
• TANSEY EM: Dark remedy: the impact of thalidomide and its revival as a vital medicine. N. Engl. J. Med. (2001) 345(3):226-227.
   Google Scholar
• SOMERS G: Pharmacologic properties of thalidomide (~ -phthalimido glutarimide), a new sedative hypnotic drug. Br. Pharmacol. (1960) 15:111-116.
   PubMed Web of Science ®Google Scholar
• MCBRIDE WG: Thalidomide and congenital abnormalities. Lancet (1961) 2:1358.
   Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al.: Inhibition of IL-12 production by thalidomide. J. Immunol. (1997) 159(10):5157-5161.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, KAPLAN G, MIRANDA A et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. (1993) 168(2):408-414.
   PubMed Web of Science ®Google Scholar
• WEBER D: Lenalinomide (CC-5013, Revlimid) and other Imids. Haematologica (2005) 90(s1):24-25. Abstract PL5.02.
   Google Scholar
• GIBSON AD, KLEM J, PRICE N et al.: 45th Annual Meeting of the American Society of Hematology December 6 – 9, 2003. Clin. Lymphoma (2004) 4(4):206-212.
   PubMedGoogle Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
   PubMed Web of Science ®Google Scholar
• WU JJ, HUANG DB, PANG KR et al.: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol. (2005) 153(2):254-273.
   PubMed Web of Science ®Google Scholar
• MATTHEWS SJ, MCCOY C: Thalidomide: a review of approved and investigational uses. Clin. Ther. (2003) 25(2):342-395.
   PubMed Web of Science ®Google Scholar
• CELGENE CORPORATION: Thalomid® (thalidomide capsules) prescribing information. Celgene Corporation, Summit (NJ) USA (2005).
   Google Scholar
• ERIKSSON T, BJORKMAN S, ROTH B et al.: Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality (1998) 10(3):223-228.
   PubMed Web of Science ®Google Scholar
• WINTER W, FRANKUS E: Thalidomide enantiomers. Lancet (1992) 339(8789):365.
   PubMed Web of Science ®Google Scholar
• ERIKSSON T, BJORKMAN S, ROTH B et al.: Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. (2000) 52(7):807-817.
   PubMed Web of Science ®Google Scholar
• HOGLUND P, ERIKSSON T, BJORKMAN S: A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. (1998) 26(4):363-383.
   PubMedGoogle Scholar
• BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its imid derivatives as anticancer agents. Nat. Rev. Cancer (2004) 4(4):314-322.
   PubMed Web of Science ®Google Scholar
• TEO SK, COLBURN WA, TRACEWELL WG et al.: Clinical pharmacokinetics of thalidomide. Clin. Pharmacokinet. (2004) 43(5):311-327.
   PubMed Web of Science ®Google Scholar
• TEO SK, COLBURN WA, THOMAS SD: Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J. Clin. Pharmacol. (1999) 39(11):1162-1168.
   PubMed Web of Science ®Google Scholar
• TEO SK, SABOURIN PJ, O’BRIEN K et al.: Metabolism of thalidomide in human microsomes, cloned human cytochrome P450 isozymes, and Hansen’s disease patients. J. Biochem. Mol. Toxicol. (2000) 14(3):140-147.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, ANAGNOSTOPOULOS A, WEBER D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J. Clin. Oncol. (2003) 21(23):4444-4454.
   PubMed Web of Science ®Google Scholar
• D’AMATO RJ, LOUGHNAN MS, FLYNN E et al.: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082-4085.
   PubMed Web of Science ®Google Scholar
• KENYON BM, BROWNE F, D’AMATO RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64(6):971-978.
   PubMed Web of Science ®Google Scholar
• LENTZSCH S, ROGERS MS, LEBLANC R et al.: S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. (2002) 62(8):2300-2305.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIBATTI D, RONCALI L et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br. J Haematol. (1994) 87(3):503-508.
   PubMed Web of Science ®Google Scholar
• GUALANDRIS A, URBINATI C, RUSNATI M et al.: Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J. Cell. Physiol. (1994) 161(1):149-159.
   PubMed Web of Science ®Google Scholar
• PITTINI V, TETI D, ARRIGO C et al.: Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF. Br. J. Haematol. (2002) 119(1):275.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIA R, SEMERARO F et al.: Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 102(9):3340-3348.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIBATTI D, PRESTA M et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 93(9):3064-3073.
   PubMed Web of Science ®Google Scholar
• PAYVANDI F, WU L, HALEY M et al.: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol. (2004) 230(2):81-88.
   PubMed Web of Science ®Google Scholar
• ZHANG M, ABE Y, MATSUSHIMA T et al.: Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk. Lymphoma (2005) 46(3):425-433.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341(21):1565-1571.
   PubMed Web of Science ®Google Scholar
• NEBEN K, MOEHLER T, KRAEMER A et al.: Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol. (2001) 115(3):605-608.
   PubMed Web of Science ®Google Scholar
• KUMAR S, WITZIG TE, DISPENZIERI A et al.: Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia (2004) 18(3):624-627.
   PubMed Web of Science ®Google Scholar
• ZHANG H, VAKIL V, BRAUNSTEIN M et al.: Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood (2005) 105(8):3286-3294.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96(9):2943-2950.
   PubMed Web of Science ®Google Scholar
• LENTZSCH S, LEBLANC R, PODAR K et al.: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia (2003) 17(1):41-44.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99(12):4525-4530.
   PubMed Web of Science ®Google Scholar
• MEIERHOFER C, WIEDERMANN CJ: New insights into the pharmacological and toxicological effects of thalidomide. Curr. Opin. Drug Discov. Devel. (2003) 6(1):92-99.
   PubMed Web of Science ®Google Scholar
• GUPTA D, TREON SP, SHIMA Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 15(12):1950-1961.
   PubMed Web of Science ®Google Scholar
• SETTLES B, STEVENSON A, WILSON K et al.: Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol. Biol. (2001) 47(7):1105-1114.
   PubMed Web of Science ®Google Scholar
• GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31(2-3):213-221.
   PubMed Web of Science ®Google Scholar
• ZWINGENBERGER K, WNENDT S: Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. (1995) 46(4):177-211.
   PubMedGoogle Scholar
• TURK BE, JIANG H, LIU JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc. Natl. Acad. Sci. USA (1996) 93(15):7552-7556.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Ann. Rev. Med. (2002) 53:629-57:629-657.
   PubMed Web of Science ®Google Scholar
• DUNZENDORFER S, HEROLD M, WIEDERMANN CJ: Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide. Immunopharmacology (1999) 43(1):59-64.
   PubMedGoogle Scholar
• OLIVER SJ: The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide. Curr. Rheumatol. Rep. (2000) 2(6):486-491.
   PubMedGoogle Scholar
• SHANNON EJ, SANDOVAL F: Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology (1995) 31(1):109-116.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163(1):380-386.
   PubMed Web of Science ®Google Scholar
• KEIFER JA, GUTTRIDGE DC, ASHBURNER BP et al.: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. (2001) 276(25):22382-22387.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood (2002) 99(11):4079-4086.
   PubMed Web of Science ®Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98(1):210-216.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, HANEKOM WA, MULLER G et al.: Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J. Infect. Dis. (2003) 187(6):946-955.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, HIDESHIMA T, AKIYAMA M et al.: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. (2005) 128(2):192-203.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, CORRAL LG, ALBERT M et al.: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187(11):1885-1892.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163(1):380-386.
   PubMed Web of Science ®Google Scholar
• ATTIGA FA, FERNANDEZ PM, WEERARATNA AT et al.: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. (2000) 60(16):4629-4637.
   PubMed Web of Science ®Google Scholar
• HUS M, DMOSZYNSKA A, KOCKI J et al.: Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia (2005) 19(8):1497-1499.
   PubMed Web of Science ®Google Scholar
• PEREZ-SIMON JA, VALVERDE B, MARTINEZ A et al.: Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. Cytometry (1999) 38(1):24-29.
   PubMedGoogle Scholar
• RAJKUMAR SV, BLOOD E, VESOLE DH et al.: Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood (2004) 104(11) Abstr. 205.
   Google Scholar
• BARLOGIE B: Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin. Hematol. (2003) 40(4 Suppl. 4):33-38.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase II study of 169 patients. Blood (2001) 98(2):492-494.
   PubMed Web of Science ®Google Scholar
• HUS M, DMOSZYNSKA A, SOROKA-WOJTASZKO M et al.: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica (2001) 86(4):404-408.
   PubMed Web of Science ®Google Scholar
• HUS I, DMOSZYNSKA A, MANKO J et al.: An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br. J. Cancer (2004) 91(11):1873-1879.
   PubMed Web of Science ®Google Scholar
• GROSBOIS B, BELISSANT E, MOREAU P et al.: Treatment of advanced multiple myeloma with thalidomide: long term follow-up in a prospective study of 121 patients. Hematol. J. (2003) 4(Suppl. 1):S226.
   Google Scholar
• NEBEN K, MOEHLER T, BENNER A et al.: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. (2002) 8(11):3377-3382.
   PubMed Web of Science ®Google Scholar
• YAKOUB-AGHA I, ATTAL M, DUMONTET C et al.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol. J. (2002) 3(4):185-192.
   PubMedGoogle Scholar
• MILESHKIN L, BIAGI JJ, MITCHELL P et al.: Multicenter Phase II trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 102(1):69-77.
   PubMed Web of Science ®Google Scholar
• MURAKAMI H, HANDA H, IMAI K et al.: [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]. Rinsho Ketsueki (2004) 45(6):468-472.
   PubMedGoogle Scholar
• PETRUCCI MT, PALUMBO G, MARTINI V et al.: Thalidomide, an active agent for multiple myeloma does not change the prognosis of plasma cell leukemia patients. Experience of a single center. Hematol. J. (2003) 4(Suppl. 1):S227.
   Google Scholar
• WU KL, SCHAAFSMA MR, LOKHORST HM et al.: [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned. Tijdschr. Geneeskd. (2002) 146(31):1445-1448.
   PubMedGoogle Scholar
• WU KL, HELGASON HH, VAN DER HB et al.: Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia (2005) 19(1):143-145.
   PubMed Web of Science ®Google Scholar
• WAAGE A, GIMSING P, JULIUSSON G et al.: Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br. J. Haematol. (2004) 125(2):149-155.
   PubMed Web of Science ®Google Scholar
• TOSI P, ZAMAGNI E, CELLINI C et al.: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 87(4):408-414.
   PubMed Web of Science ®Google Scholar
• HUANG SY, TANG JL, YAO M et al.: Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann. Hematol. (2003) 82(9):558-564.
   PubMed Web of Science ®Google Scholar
• BLADE J, PERALES M, ROSINOL L et al.: Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br. J. Haematol. (2001) 113(2):422-424.
   PubMed Web of Science ®Google Scholar
• CIBEIRA MT, ROSINOL L, ESTEVE J et al.: Talidomide in refractory and relapsed multiple myeloma: duration of response. Haematologica (2005) 90(Suppl. 1):140 Abstr.
   Google Scholar
• KUMAR S, GERTZ MA, DISPENZIERI A et al.: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin. Proc. (2003) 78(1):34-39.
   PubMed Web of Science ®Google Scholar
• MOHTY M, ATTAL M, MARIT G et al.: Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. (2005) 35(2):165-169.
   PubMed Web of Science ®Google Scholar
• WECHALEKAR AD, CHEN CI, SUTTON D et al.: Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk. Lymphoma (2003) 44(7):1147-1149.
   PubMed Web of Science ®Google Scholar
• JULIUSSON G, CELSING F, TURESSON I et al.: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol. (2000) 109(1):89-96.
   PubMed Web of Science ®Google Scholar
• KEES M, DIMOU G, SILLABER C et al.: Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk. Lymphoma (2003) 44(11):1943-1946.
   PubMed Web of Science ®Google Scholar
• KNELLER A, RAANANI P, HARDAN I et al.: Therapy with thalidomide in refractory multiple myeloma patients – the revival of an old drug. Br. J. Haematol. (2000) 108(2):391-393.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, FONSECA R, DISPENZIERI A et al.: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. (2000) 75(9):897-901.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, GERTZ MA, KYLE RA et al.: Current therapy for multiple myeloma. Mayo Clin. Proc. (2002) 77(8):813-822.
   PubMed Web of Science ®Google Scholar
• TOSI P, RONCONI S, ZAMAGNI E et al.: Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 86(4):409-413.
   PubMed Web of Science ®Google Scholar
• ALEGRE A, AGUADO B, GIL-FERNÁNDEZ JJ et al.: Long-term treament with low dose thalidomide in multiple myeloma. Haematologica (2005) 90(Suppl. 1):140 Abstr. PL.706.
   Google Scholar
• ANAGNOSTOPOULOS A, HAMILOS G, ZORZOU MP et al.: Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk. Lymphoma (2004) 45(1):113-116.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. (2001) 12(7):991-995.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, GIACCONE L, BERTOLA A et al.: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 86(4):399-403.
   PubMed Web of Science ®Google Scholar
• BOULIN M, BLANCHET F, ISAMBERT N et al.: [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Therapie (2002) 57(6):524-529.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, WEBER D, ANAGNOSTOPOULOS A et al.: Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin. Hematol. (2003) 40(4 Suppl. 4):3-7.
   PubMed Web of Science ®Google Scholar
• ANAGNOSTOPOULOS A, WEBER D, RANKIN K et al.: Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. (2003) 121(5):768-771.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, BERTOLA A, FALCO P et al.: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J. (2004) 5(4):318-324.
   PubMedGoogle Scholar
• TOSI P, ZAMAGNI E, CELLINI C et al.: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur. J. Haematol. (2004) 73(2):98-103.
   PubMed Web of Science ®Google Scholar
• CARAVITA T, SINISCALCHI A, SANTINELLI S et al.: Low dose thalidomide plus dexamethasone for relapsed/refractory multiple myeloma: a single center expèrience. Haemtol. J. (2003) 4(Suppl. 1):S237 Abstr. 333.
   Google Scholar
• GARDYN J: Thalidomide with continuous low-dose dexamethasone for multiple myeloma. J. Clin. Oncol. (2005) 23(6):1323.
   PubMedGoogle Scholar
• BARLOGIE B, ZANGARI M, SPENCER T et al.: Thalidomide in the management of multiple myeloma. Semin. Hematol. (2001) 38(3):250-259.
   PubMed Web of Science ®Google Scholar
• GARCIA-SANZ R, GONZALEZ-FRAILE MI, SIERRA M et al.: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol. J. (2002) 3(1):43-48.
   PubMedGoogle Scholar
• GARCIA-SANZ R, GONZALEZ-PORRAS JR, HERNANDEZ JM et al.: The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia (2004) 18(4):856-863.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, HAMILOS G, ZOMAS A et al.: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol. J. (2004) 5(2):112-117.
   PubMedGoogle Scholar
• KYRIAKOU C, THOMSON K, D’SA S et al.: Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br. J. Haematol. (2005) 129(6):763-770.
   PubMed Web of Science ®Google Scholar
• DI RAIMONDO F, PENNISI A, BUGLIO D et al.: Combination of thalidomide, cyclophosphamide, and dexamethasone in refractory-relapsed multiple myeloma. Hematol. J. (2003) 4(Suppl. 1):S241 Abstr. 343.
   Google Scholar
• KROPFF MH, LANG N, BISPING G et al.: Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br. J. Haematol. (2003) 122(4):607-616.
   PubMed Web of Science ®Google Scholar
• MOEHLER TM, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98(13):3846-3848.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA: Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist (2003) 8(Suppl. 3):39-45.
   PubMed Web of Science ®Google Scholar
• SRKALOVIC G, ELSON P, TREBISKY B et al.: Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol. (2002) 19(4):219-226.
   PubMed Web of Science ®Google Scholar
• LEE CK, BARLOGIE B, MUNSHI N et al.: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. Oncol. (2003) 21(14):2732-2739.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA: New treatment strategies for multiple myeloma. Semin. Hematol. (2004) 41(4 Suppl. 7):2-8.
   PubMed Web of Science ®Google Scholar
• WEBER D, RANKIN K, GAVINO M et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21(1):16-19.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV: Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Semin. Hematol. (2003) 40(4 Suppl. 4):17-22.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, GERTZ MA, LACY MQ et al.: Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 17(4):775-779.
   PubMed Web of Science ®Google Scholar
• CAVO M, ZAMAGNI E, TOSI P et al.: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica (2004) 89(7):826-831.
   PubMed Web of Science ®Google Scholar
• WANG M, WEBER DM, DELASALLE K et al.: Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am. J. Hematol. (2005) 79(3):194-197.
   PubMed Web of Science ®Google Scholar
• CAVO M, ZAMAGNI E, TOSI P et al.: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood (2005) 106(1):35-39.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV: Multiple myeloma: the death of VAD as initial therapy. Blood (2005) 106(1):2-3.
   Web of Science ®Google Scholar
• PALUMBO A, BERTOLA A, MUSTO P et al.: Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer (2005) 104(7):1428-1433.
   PubMed Web of Science ®Google Scholar
• ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E et al.: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. (2004) 15(1):134-138.
   PubMed Web of Science ®Google Scholar
• SCHUTT P, EBELING P, BUTTKEREIT U et al.: Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur. J. Haematol. (2005) 74(1):40-46.
   PubMed Web of Science ®Google Scholar
• OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med. (2001) 344(25):1951-1952.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, ANAISSIE E, BARLOGIE B et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 98(5):1614-1615.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, BARLOGIE B, ANAISSIE E et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. (2004) 126(5):715-721.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, RASMUSSEN E, SHAUGHNESSY J et al.: Total therapy for newly diagnosed multiple myeloma: the Arkansas Experience with 1000 patients treated with Total Therapy 1, 2 and 3. Haematologica (2005) 90(Suppl. 1):19 Abstr. PL4.04.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, WEBER D, GIRALT S et al.: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann. Oncol. (2002) 13(7):1116-1119.
   PubMed Web of Science ®Google Scholar
• SANTOS ES, GOODMAN M, BYRNES JJ et al.: Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology (2004) 9(1):35-39.
   PubMedGoogle Scholar
• STEWART AK, CHEN CI, HOWSON-JAN K et al.: Results of a multicenter randomized Phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. (2004) 10(24):8170-8176.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, LEYVRAZ S et al.: Maintenance treatment with thalidomide and pamidronate after autologus transplantation for myeloma: Second analysis of a prospective randomized study of the intergroupe francophone du myeloma. Haematologica (2005) 90 (Suppl. 1):17 Abstr. PL4.01.
   Google Scholar
• DURIE BG: Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin. Oncol. (2002) 29(6 Suppl. 17):34-38.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, WEBER D: Thalidomide for resistant and relapsing myeloma. Semin. Hematol. (2005) 37(Suppl.):22-25.
   Google Scholar
• KROGER N, SHIMONI A, ZAGRIVNAJA M et al.: Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood (2004) 104(10):3361-3363.
   PubMed Web of Science ®Google Scholar
• OFFIDANI M, CORVATTA L, MARCONI M et al.: Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur. J. Haematol. (2004) 72(6):403-409.
   PubMed Web of Science ®Google Scholar
• RIBAS C, COLLEONI G, ALMEIDA M et al.: Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. Acta Oncol. (2004) 43(2):215-216.
   PubMed Web of Science ®Google Scholar
• STEURER M, SPIZZO G, MITTERER M et al.: Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie (2004) 27(2):150-154.
   PubMedGoogle Scholar
• JOHNSTON RE, ABDALLA SH: Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk. Lymphoma (2002) 43(2):351-354.
   PubMed Web of Science ®Google Scholar
• LELEU X, MAGRO L, FAWAZ A et al.: Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood (2002) 100(4):1519-1520.
   PubMed Web of Science ®Google Scholar
• LEE FC: Second response to lower-dose thalidomide in a patient with multiple myeloma. Blood (2002) 99(11):4248.
   PubMed Web of Science ®Google Scholar
• WAAGE A, ROMSTAD L, BRENNE AT: Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. Blood (2002) 100(1):380b.
   Google Scholar
• OAKERVEE H, GUPTA V, SMITH. ML: Response to thalidomide can be predicted by paraprotein quantitation 14 days after initiating therapy. Br. J. Haematol. (2001) 113 (Suppl.):40.
   PubMed Web of Science ®Google Scholar
• NEBEN K, MOEHLER T, EGERER G et al.: High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res. (2001) 7(9):2675-2681.
   PubMed Web of Science ®Google Scholar
• NEBEN K, MYTILINEOS J, MOEHLER TM et al.: Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood (2002) 100(6):2263-2265.
   PubMed Web of Science ®Google Scholar
• THOMPSON MA, WITZIG TE, KUMAR S et al.: Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br. J. Haematol. (2003) 123(2):305-308.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, HERNANDEZ MO, CARVALHO DS et al.: Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed. Pharmacother. (2002) 56(1):13-19.
   PubMed Web of Science ®Google Scholar
• NOORMOHAMED FH, YOULE MS, HIGGS CJ et al.: Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res. Hum. Retroviruses (1999) 15(12):1047-1052.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, GERTZ MA, WITZIG TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N. Engl. J. Med. (2000) 343(13):972-973.
   PubMed Web of Science ®Google Scholar
• HALL VC, EL AZHARY RA, BOUWHUIS S et al.: Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol. (2003) 48(4):548-552.
   PubMed Web of Science ®Google Scholar
• BLADE J, ROSINOL L: Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies. Clin. Lymphoma (2003) 3(4):247-248.
   PubMedGoogle Scholar
• FAHDI IE, GADDAM V, SAUCEDO JF et al.: Bradycardia during therapy for multiple myeloma with thalidomide. Am. J. Cardiol. (2004) 93(8):1052-1055.
   PubMed Web of Science ®Google Scholar
• BLADE J, ESTEVE J, ROSINOL L et al.: Thalidomide in refractory and relapsing multiple myeloma. Semin. Oncol. (2001) 28(6):588-592.
   PubMed Web of Science ®Google Scholar
• TOSI P, ZAMAGNI E, CELLINI C et al.: Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. (2005) 74(3):212-216.
   PubMed Web of Science ®Google Scholar
• BASTUJI-GARIN S, OCHONISKY S, BOUCHE P et al.: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J. Invest. Dermatol. (2002) 119(5):1020-1026.
   PubMed Web of Science ®Google Scholar
• MAURER T, PONCELET A, BERGER T: Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch. Dermatol. (2004) 140(7):845-849.
   PubMedGoogle Scholar
• ISOARDO G, BERGUI M, DURELLI L et al.: Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol. Scand. (2004) 109(3):188-193.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY V, CORNBLATH DR, CORSE A et al.: Thalidomide-induced neuropathy. Neurology (2002) 59(12):1872-1875.
   PubMed Web of Science ®Google Scholar
• MOLLOY FM, FLOETER MK, SYED NA et al.: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve (2001) 24(8):1050-1057.
   PubMed Web of Science ®Google Scholar
• OCHONISKY S, VERROUST J, BASTUJI-GARIN S et al.: Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. (1994) 130(1):66-69.
   PubMed Web of Science ®Google Scholar
• MARKARIAN Y, WULFF EA, SIMPSON DM: Peripheral neuropathy in HIV disease. AIDS Clin. Care (1998) 10(12):89-91, 93, 98.
   PubMed Web of Science ®Google Scholar
• FULLERTON PM, O’SULLIVAN DJ: Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J. Neurol. Neurosurg. Psychiatry (1968) 31(6):543-551.
   PubMed Web of Science ®Google Scholar
• SRKALOVIC G, CAMERON MG, RYBICKI L et al.: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer (2004) 101(3):558-566.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, JAGANNATH S, DESIKAN KR et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 93(1):55-65.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20(21):4319-4323.
   PubMed Web of Science ®Google Scholar
• BOWCOCK SJ, RASSAM SM, WARD SM et al.: Thromboembolism in patients on thalidomide for myeloma. Hematology (2002) 7(1):51-53.
   PubMedGoogle Scholar
• MOEHLER TM, HILLENGASS J, GOLDSCHMIDT H et al.: Antiangiogenic therapy in hematologic malignancies. Curr. Pharm. Des. (2004) 10(11):1221-1234.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, SIEGEL E, BARLOGIE B et al.: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood (2002) 100(4):1168-1171.
   PubMed Web of Science ®Google Scholar
• URBAUER E, KAUFMANN H, NOSSLINGER T et al.: Thromboembolic events during treatment with thalidomide. Blood (2002) 99(11):4247-4248.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MA, KARAM MA, REED J et al.: Pegylated doxorubicin in combination with immune-moculators and arsenic-containing regimens for the management of multiple myeloma. Haematologica (2005) 90(Suppl. 1):25-26.
   PubMed Web of Science ®Google Scholar
• OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med. (2001) 344(25):1951-1952.
   PubMed Web of Science ®Google Scholar
• KAUSHAL V, KAUSHAL GP, MELKAVERI SN et al.: Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost. (2004) 2(2):327-334.
   PubMed Web of Science ®Google Scholar
• MINNEMA MC, FIJNHEER R, DE GROOT PG et al.: Extremely high levels of von Willebrand factor antigen and of procoagulant Factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost. (2003) 1(3):445-449.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, BARLOGIE B, THERTULIEN R et al.: Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma (2003) 4(1):32-35.
   PubMedGoogle Scholar
• WEBER D: Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control (2003) 10(5):375-383.
   PubMedGoogle Scholar
• DE SAVARY N, LEE R, VAIDYA B: Severe hypothyroidism after thalidomide treatment. J. R. Soc. Med. (2004) 97(9):443.
   PubMed Web of Science ®Google Scholar
• BADROS AZ, SIEGEL E, BODENNER D et al.: Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am. J. Med. (2002) 112(5):412-413.
   PubMed Web of Science ®Google Scholar
• MURDOCH JM, CAMPBELL GD: Antithyroid activity of N-phthaloyl glutamic acid. Br. Med. J. (1958) 1:84-85.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, ELEUTHERAKIS-PAPAIAKOVOU V: Adverse effects of thalidomide administration in patients with neoplastic diseases. Am. J. Med. (2004) 117(7):508-515.
   PubMed Web of Science ®Google Scholar